Energized by the opening of a second front in a high-stakes gene therapy collaboration with Abbvie Inc., investors in Voyager Therapeutics Inc. lifted company shares (NASDAQ:VYGR) 22.9 percent to $13.12 Friday. Under terms of the deal, Voyager's second in Parkinson's disease (PD) in as many months, Abbvie will pay the company $65 million up front in exchange for an exclusive option to license vectorized antibodies targeting misfolded alpha-synuclein proteins for synucleinopathies, like PD. Voyager will foot the bill for developing and testing the compounds through phase I.